COVID-19 Antiviral and Treatment Candidates: Current Status

키워드

참고문헌 (147)

1. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
2. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
3. "COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020"[URL]
4. Lauer SA, "The incubation period of coronavirus disease 2019(COVID-19)from publicly reported confirmed cases : estimation and application", Ann Intern Med, 172, pp.577~582 (2020)
5. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
6. He X, "Temporal dynamics in viral shedding and transmissibility of COVID-19", Nat Med, 26, pp.672~675 (2020)
7. Lippi G, "COVID-19 : unravelling the clinical progression of nature's virtually perfect biological weapon", Ann Transl Med, 8, pp.693~ (2020)
8. Henry BM, "Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19 : a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis", Clin Chim Acta, 507, pp.167~173 (2020)
9. Ragab D, "The COVID-19 cytokine storm; what we know so far", Front Immunol, 11, pp.1446~ (2020)
10. Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19) : a review", JAMA, 324, pp.782~793 (2020)
11. Abou-Ismail MY, "The hypercoagulable state in COVID-19 : incidence, pathophysiology, and management", Thromb Res, 194, pp.101~115 (2020)
12. Carfì A, "Persistent symptoms in patients after acute COVID-19", JAMA, 324, pp.603~605 (2020)
13. Ahmed M, "Multisystem inflammatory syndrome in children : a systematic review", EClinicalMedicine, 26, pp.100527~ (2020)
14. adenine C-nucleoside(GS-5734)for the treatment of Ebola and emerging viruses, "J Med Chem", 2017, 1648~1661
15. Gordon CJ, "Remdesivir is a directacting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency", J Biol Chem, 295, pp.6785~6797 (2020)
16. Mulangu S, "A randomized, controlled trial of Ebola virus disease therapeutics", N Engl J Med, 381, pp.2293~2303 (2019)
17. Malin JJ, "Remdesivir against COVID-19 and other viral diseases", Clin Microbiol Rev, 34, pp.e00162~e00120 (2020)
18. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
19. Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
20. Grein J, "Compassionate use of remdesivir for patients with severe COVID-19", N Engl J Med, 382, pp.2327~2336 (2020)
21. Beigel JH, "Remdesivir for the treatment of COVID-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
22. WHO Solidarity Trial Consortium, "Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results", New England Journal of Medicine, 384(6), pp.497~511 (2021), Massachusetts Medical Society[DOI]
23. Corbett AH, "Kaletra(lopinavir", ritonavir), 2002, pp.36, 1193~1203
24. Kumar Y, "In silico prediction of potential inhibitors for the main protease of SARSCoV-2 using molecular docking and dynamics simulation based drug-repurposing", J Infect Public Health, 13, pp.1210~1223 (2020)
25. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
26. Park SY, "Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers", J Hosp Infect, 101, pp.42~46 (2019)
27. Ullrich S, "The SARS-CoV-2 main protease as drug target", Bioorg Med Chem Lett, 30, pp.127377~ (2020)
28. Wang Z, "Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment", Biosci Trends, 14, pp.64~68 (2020)
29. Kim JY, "Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea : the application of lopinavir", ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR, 2020, pp.35, e88~
30. Li Y, "Efficacy and safety of lopinavir", ritonavir or arbidol in adult patients with mild, Med(N Y), pp.2020, 1[DOI]
31. Horby PW, "Lopinavir-ritonavir in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 396, pp.1345~1352 (2020)
32. ""Solidarity" clinical trial for COVID-19 treatments"[URL]
33. Leyssen P, "The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase", J Virol, 79, pp.1943~1947 (2005)
34. Crotty S, "RNA virus error catastrophe : direct molecular test by using ribavirin", Proc Natl Acad Sci U S A, 98, pp.6895~6900 (2001)
35. Rigopoulou EI, "Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus", Antiviral Res, 75, pp.36~42 (2007)
36. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
37. Morgenstern B, "Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines", Biochem Biophys Res Commun, 326, pp.905~908 (2005)
38. Falzarano D, "Treatment with interferon-α2b and ribavirin improves outcome in MERSCoV-infected rhesus macaques", Nat Med, 19, pp.1313~1317 (2013)
39. Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection : a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
40. Arabi YM, "Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome : a multicenter observational study", Clin Infect Dis, 70, pp.1837~1844 (2020)
41. Tong S, "Ribavirin therapy for severe COVID-19 : a retrospective cohort study", Int J Antimicrob Agents, 56, pp.106114~ (2020)
42. Hung IFN, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
43. Huang YQ, "No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir", ritonavir plus interferon-alpha, and ribavirin plus lopinavir, Front Pharmacol, pp.2020, 11[DOI]
44. Guedj J, "Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life", Proc Natl Acad Sci U S A, 110, pp.3991~3996 (2013)
45. Stedman C, "Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C : a review of its clinical potential", Therap Adv Gastroenterol, 7, pp.131~140 (2014)
46. Ferreira AC, "Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication", Antimicrob Agents Chemother, 63, pp.e01389~e01318 (2019)
47. Elfiky AA, "Anti-HCV, nucleotide inhibitors, repurposing against COVID-19", Life Sci, 248, pp.117477~ (2020)
48. Jácome R, "Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic", Sci Rep, 10, pp.9294~ (2020)
49. Jockusch S, "Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir", Sci Rep, 10, pp.16577~ (2020)
50. Bahadur Gurung A, "Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme", J King Saud Univ Sci, 32, pp.2845~2853 (2020)
51. Sacramento CQ, "The in vitro antiviral activity of the antihepatitis C virus(HCV)drugs daclatasvir and sofosbuvir against SARS-CoV-2", bioRxiv. doi:10.1101, 2020 (2020)
52. Sadeghi A, "Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection(COVID-19) : a randomized controlled trial", J Antimicrob Chemother, 75, pp.3379~3385 (2020)
53. Eslami G, "The impact of sofosbuvir", daclatasvir or ribavirin in patients with severe COVID-19, 2020, pp.75, 3366~3372
54. Roozbeh F, "Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial", J Antimicrob Chemother (2020)[DOI]
55. Furuta Y, "Mechanism of action of T-705 against influenza virus", Antimicrob Agents Chemother, 49, pp.981~986 (2005)
56. Mendenhall M, "T-705(favipiravir)inhibition of arenavirus replication in cell culture", Antimicrob Agents Chemother, 55, pp.782~787 (2011)
57. Delang L, "Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir(T-705), a broad-spectrum antiviral", J Antimicrob Chemother, 69, pp.2770~2784 (2014)
58. Borrego B, "Lethal mutagenesis of rift valley fever virus induced by favipiravir", Antimicrob Agents Chemother, 63, pp.e00669~e00619 (2019)
59. de Ávila AI, "Lethal mutagenesis of hepatitis C virus induced by favipiravir", PLoS One, 11, pp.e0164691~ (2016)
60. Escribano-Romero E, "Extinction of West Nile virus by favipiravir through lethal mutagenesis", Antimicrob Agents Chemother, 61, pp.e01400~e01417 (2017)
61. Shannon A, "Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis", Nat Commun, 11, pp.4682~ (2020)
62. Kaptein SJF, "Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity", Proc Natl Acad Sci U S A, 117, pp.26955~26965 (2020)
63. Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study", Engineering(Beijing), 6, pp.1192~1198 (2020)
64. Chen C, "Favipiravir versus arbidol for COVID-19 : a randomized clinical trial", medRxiv doi: 10.1101, 2020 (2020)
65. Doi Y, "A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19", Antimicrob Agents Chemother, 64, pp.e01897~e01820 (2020)
66. Kadam RU, "Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol", Proc Natl Acad Sci U S A, 114, pp.206~214 (2017)
67. Pécheur EI, "The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses", J Virol, 90, pp.3086~3092 (2016)
68. Shi L, "Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo", Arch Virol, 152, pp.1447~1455 (2007)
69. Wei XF, "Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay", Antimicrob Agents Chemother, 62, pp.e01302~e01318 (2018)
70. Wang X, "The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro", Cell Discov, 6, pp.28~ (2020)
71. Lian N, "Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019 : a retrospective study", Clin Microbiol Infect, 26, pp.917~921 (2020)
72. Xu P, "Arbidol", IFN-α2b therapy for patients with corona virus disease 2019 : a retrospective multicenter cohort study, 2020, pp.22, 200~205
73. Nojomi M, "Effect of Arbidol(umifenovir)on COVID-19 : a randomized controlled trial", BMC Infect Dis, 20, pp.954~ (2020)
74. Devaux CA, "New insights on the antiviral effects of chloroquine against coronavirus : what to expect for COVID-19", Int J Antimicrob Agents, 55, pp.105938~ (2020)
75. Hashem AM, "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections : a narrative review", Travel Med Infect Dis, 35, pp.101735~ (2020)
76. Khan M, "Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells", J Med Virol, 82, pp.817~824 (2010)
77. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an openlabel non-randomized clinical trial", Int J Antimicrob Agents, 56, pp.105949~ (2020)
78. RECOVERY Collaborative GroupHorby P, "Effect of hydroxychloroquine in hospitalized patients with COVID-19", N Engl J Med, 383, pp.2030~2040 (2020)
79. Gorabi AM, "Antiviral effects of statins", Prog Lipid Res, 79, pp.101054~ (2020)
80. Takahashi T, "Function of membrane rafts in viral lifecycles and host cellular response", Biochem Res Int, 2011, pp.245090~ (2011)
81. Fecchi K, "Coronavirus interplay with lipid rafts and autophagy unveils promising therapeutic targets", Front Microbiol, 11, pp.1821~ (2020)
82. Diamantis E, "The anti-inflammatory effects of statins on coronary artery disease : an updated review of the literature", Curr Cardiol Rev, 13, pp.209~216 (2017)
83. Mansur A, "Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome(ARDS)depends on ARDS severity : a prospective observational cohort study", BMC Med, 13, pp.128~ (2015)
84. Zhang XJ, "In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19", Cell Metab, 32, pp.176.e4~187.e4 (2020)
85. De Spiegeleer A, "The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19infection among nursing home residents", J Am Med Dir Assoc, 21, pp.909.e2~914.e2 (2020)
86. Daniels LB, "Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients", Am J Cardiol, 136, pp.149~155 (2020)
87. Moeller R, "Effect of statins on SARS-CoV-2 infection", medRxiv doi:10.1101, 2021 (2020)
88. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271.e8~280.e8 (2020)
89. Hoffmann M, "nafamostat mesylate blocks activation of SARS-CoV-2 : new treatment option for COVID-19", Antimicrob Agents Chemother, 64, pp.e00754~ (2020)
90. 이상택, "The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding", Childhood Kidney Diseases, 18(2), pp.98~105 (2014), 대한소아신장학회
91. Choi JY, "Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial", Medicine (Baltimore), 94, pp.e2392~ (2015)
92. Blanco-Melo D, "Imbalanced host response to SARS-CoV-2 drives development of COVID-19", Cell, 181, pp.1036.e9~1045.e9 (2020)
93. Hadjadj J, "Impaired type I interferon activity and inflammatory responses in severe COVID-19patients", Science, 369, pp.718~724 (2020)
94. Zhang Q, "Inborn errors of type I IFN immunity in patients with life-threatening COVID-19", Science, 370, pp.eabd4570~ (2020)
95. Bastard P, "Autoantibodies against type I IFNs in patients with life-threatening COVID-19", Science, 370, pp.eabd4585~ (2020)
96. Vanderheiden A, "Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures", J Virol, 94, pp.e00985~e00920 (2020)
97. Zhou Z, "Heightened innate immune responses in the respiratory tract of COVID-19 patients", Cell Host Microbe, 27, pp.883~890 (2020)
98. Fu W, "A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19", EClinicalMedicine, 25, pp.100478~ (2020)
99. Wang N, "Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients", Cell Host Microbe, 28, pp.455.e2~464.e2 (2020)
100. Davoudi-Monfared E, "A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19", Antimicrob Agents Chemother, 64, pp.e01061~e01020 (2020)
101. Pereda R, "Therapeutic effectiveness of interferon-α2b against COVID-19 : the cuban experience", J Interferon Cytokine Res, 40, pp.438~442 (2020)
102. Rahmani H, "Interferon β-1b in treatment of severe COVID-19 : a randomized clinical trial", Int Immunopharmacol, 88, pp.106903~ (2020)
103. Monk PD, "Safety and efficacy of inhaled nebulised interferon beta-1a(SNG001)for treatment of SARS-CoV-2infection : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Respir Med, 9, pp.196~206 (2021)
104. Focosi D, "Convalescent plasma therapy for COVID-19 : state of the art", Clin Microbiol Rev, 33, pp.e00072~e00020 (2020)
105. Erkurt MA, "Life-saving effect of convalescent plasma treatment in COVID-19 disease : clinical trial from eastern Anatolia", Transfus Apher Sci, 59, pp.102867~ (2020)
106. Li L, "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19 : a randomized clinical trial", JAMA, 324, pp.460~470 (2020)
107. Ventura A. Simonovich, "A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia", New England Journal of Medicine, 384(7), pp.619~629 (2021), Massachusetts Medical Society[DOI]
108. Wang C, "A human monoclonal antibody blocking SARS-CoV-2 infection", Nat Commun, 11, pp.2251~ (2020)
109. Wan J, "Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection", Cell Reports, 32, pp.107918~ (2020)
110. Wu Y, "A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2", Science, 368, pp.1274~1278 (2020)
111. Brouwer PJM, "Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability", Science, 369, pp.643~650 (2020)
112. Chen P, "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19", N Engl J Med, 384, pp.229~237 (2021)
113. Weinreich DM, "REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19", N Engl J Med, 384, pp.238~251 (2021)
114. "Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59in patients with mild symptoms"[URL]
115. Del Valle DM, "An inflammatory cytokine signature predicts COVID-19 severity and survival", Nat Med, 26, pp.1636~1643 (2020)
116. Guaraldi G, "Tocilizumab in patients with severe COVID-19 : a retrospective cohort study", Lancet Rheumatol, 2, pp.e474~e484 (2020)
117. Biran N, "Tocilizumab among patients with COVID-19 in the intensive care unit : a multicentre observational study", Lancet Rheumatol, 2, pp.e603~e612 (2020)
118. Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab", Proc Natl Acad Sci U S A, 117, pp.10970~10975 (2020)
119. Klopfenstein T, "Tocilizumab therapy reduced intensive care unit admissions and", or mortality in COVID-19 patients, 2020, pp.50, 397~400
120. Garth W. Strohbehn, "COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia", Clinical Pharmacology & Therapeutics, 109(3), pp.688~696 (2021), Wiley[DOI]
121. Salama C, "Tocilizumab in patients hospitalized with COVID-19 pneumonia", N Engl J Med, 384, pp.20~30 (2021)
122. Stone JH, "Efficacy of tocilizumab in patients hospitalized with COVID-19", N Engl J Med, 383, pp.2333~2344 (2020)
123. Tsai A, "Impact of tocilizumab administration on mortality in severe COVID-19", Sci Rep, 10, pp.19131~ (2020)
124. "Sanofi provides update on Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19patients outside the U.S"[URL]
125. Gritti G, "IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure : an observational cohort study", medRxiv doi: 10.1101, 2020 (2020)
126. Harrison C, "Focus shifts to antibody cocktails for COVID-19 cytokine storm", Nat Biotechnol, 38, pp.905~908 (2020)
127. De Luca G, "GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation : a single-centre, prospective cohort study", Lancet Rheumatol, 2, pp.e465~e473 (2020)
128. "Kiniksa announces data from U.S. investigator-initiated study of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation"[URL]
129. Cavalli G, "Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation : a retrospective cohort study", Lancet Rheumatol, 2, pp.e325~e331 (2020)
130. Huet T, "Anakinra for severe forms of COVID-19 : a cohort study", Lancet Rheumatol, 2, pp.e393~e400 (2020)
131. Balkhair A, "Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy : results of a prospective, open-label, interventional study", Int J Infect Dis, 103, pp.288~296 (2021)
132. La Rosée F, "The Janus kinase 1", 2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation, 2020, pp.34, 1805~1815
133. Capochiani E, "Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol", Front Med(Lausanne), 7, pp.466~ (2020)
134. Cao Y, "Ruxolitinib in treatment of severe coronavirus disease 2019(COVID-19) : a multicenter, single-blind, randomized controlled trial", J Allergy Clin Immunol, 146, pp.137.e3~146.e3 (2020)
135. Innes AJ, "Ruxolitinib for tocilizumab-refractory severe COVID-19 infection", Br J Haematol, 190, pp.e198~e200 (2020)
136. "Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 2020"[URL]
137. D'Alessio A, "Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia", Leukemia, 35, pp.635~638 (2021)
138. Cantini F, "Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study", J Infect, 81, pp.647~679 (2020)
139. Andre C. Kalil, "Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19", New England Journal of Medicine, 384(9), pp.795~807 (2021), Massachusetts Medical Society[DOI]
140. Wu D, "TH17 responses in cytokine storm of COVID-19 : an emerging target of JAK2 inhibitor Fedratinib", J Microbiol Immunol Infect, 53, pp.368~370 (2020)
141. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
142. RECOVERY Collaborative Group, "Dexamethasone in Hospitalized Patients with Covid-19", New England Journal of Medicine, 384(8), pp.693~704 (2021), Massachusetts Medical Society[DOI]
143. Tomazini BM, "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : the CoDEX randomized clinical trial", JAMA, 324, pp.1307~1316 (2020)
144. Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19 : a randomized clinical trial", JAMA, 324, pp.1298~1306 (2020)
145. Angus DC, "Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19 : the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial", JAMA, 324, pp.1317~1329 (2020)
146. WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : a meta-analysis", JAMA, 324, pp.1330~1341 (2020)
147. "Corticosteroids for COVID-19: living guidance"[URL]

관련 논문AI추천